AMGN Earnings Preview: $4.73 EPS Expected April 30

By Danny Kontos

April 29, 2026

5 min read

Share with:

preferred News SourceSelectMeykaasyourpreferredNewsSource

Key Points

Analysts expect $4.73 EPS and $8.58B revenue on April 30

Amgen beat revenue estimates in three consecutive quarters

EPS estimate significantly lower than recent quarters suggests caution

Strong margins and cash flow support potential beat scenario

Amgen Inc. (AMGN) reports earnings on April 30, 2026, after market close. Analysts expect earnings per share of $4.73 and revenue of $8.58 billion. The pharmaceutical giant trades at $339.57 with a market cap of $183.05 billion. Investors will scrutinize whether the company can maintain its recent earnings momentum. Recent quarters show mixed results, with some beats and misses. Understanding what to expect helps investors prepare for potential stock movement. We’ll break down the estimates, historical trends, and key metrics to watch.

Earnings Estimates and What They Mean

Analysts project AMGN will deliver $4.73 earnings per share and $8.58 billion in quarterly revenue. These estimates represent a critical benchmark for the market.

EPS Estimate Analysis

The $4.73 EPS estimate sits below the most recent beat of $6.02 in August 2025. However, it’s higher than the $4.73 estimate from May 2025, which the company beat with $4.90 actual EPS. This suggests analysts are being cautious. The estimate reflects expectations for steady but not explosive earnings growth. A beat would signal strong operational execution and pricing power in Amgen’s core franchises.

Revenue Expectations and Historical Context

The $8.58 billion revenue estimate represents a modest outlook compared to recent quarters. Amgen’s last four quarters show strong revenue performance, ranging from $8.15 billion to $9.87 billion.

Recent Revenue Trends

Amgen beat revenue estimates in three of the last four quarters. In February 2026, the company delivered $9.87 billion versus $9.47 billion expected. August 2025 saw $9.17 billion actual versus $8.94 billion estimated. May 2025 brought $8.15 billion against $8.06 billion expected. This track record suggests Amgen has pricing strength and solid demand for its portfolio. The current $8.58 billion estimate appears conservative relative to recent performance, potentially setting up another beat opportunity.

Beat or Miss Prediction Based on Historical Patterns

Amgen’s recent earnings history reveals a consistent pattern of beating revenue estimates. The company has exceeded revenue expectations in three consecutive quarters through February 2026.

Pattern Analysis

On the EPS side, results are more mixed. The company beat EPS estimates in August and May 2025 but faced challenges in other periods. Given the conservative revenue estimate of $8.58 billion and Amgen’s demonstrated ability to drive pricing and volume, a revenue beat appears likely. EPS could surprise if the company maintains operating margins. However, investors should note that the $4.73 EPS estimate is significantly lower than recent quarters, suggesting either seasonal weakness or analyst caution about near-term headwinds.

Key Metrics and What Investors Should Watch

Beyond headline numbers, several metrics will determine whether this earnings report satisfies investors. Amgen’s operational efficiency and cash generation matter as much as top-line growth.

Operating Margin and Cash Flow

Amgen maintains a strong net profit margin of 20.97% and operating margin of 27.99%. Free cash flow per share stands at $15.03, supporting the company’s $9.66 dividend per share. Watch for any deterioration in margins or cash conversion. The company’s debt-to-equity ratio of 6.31 is elevated, so strong cash generation remains critical. Additionally, monitor guidance for the remainder of 2026. Any commentary on biosimilar competition, regulatory headwinds, or pipeline progress could drive stock movement. The company’s PE ratio of 23.86 suggests the market prices in moderate growth expectations.

Final Thoughts

Amgen’s April 30 earnings report arrives with modest EPS expectations but conservative revenue guidance that could set up another beat. The company’s three-quarter streak of revenue outperformance and strong operational margins support a positive outlook. However, the significantly lower EPS estimate compared to recent quarters warrants caution. Investors should focus on margin stability, cash flow generation, and management guidance on competitive pressures and pipeline progress. With a Meyka AI grade of B+, AMGN reflects solid fundamentals but faces valuation and competitive headwinds. The stock’s recent 0.18% decline suggests market uncertainty ahead of the report.

FAQs

What EPS and revenue does Amgen need to beat estimates?

Analysts expect $4.73 EPS and $8.58 billion revenue. Amgen has beaten revenue estimates in three consecutive quarters, suggesting it could exceed the $8.58 billion target. An EPS beat would require exceeding $4.73, though recent quarters show higher earnings.

How does the $4.73 EPS estimate compare to recent quarters?

The estimate is significantly lower than recent results. August 2025 delivered $6.02 EPS, and May 2025 brought $4.90 EPS. The lower estimate may reflect seasonal factors or analyst caution about near-term headwinds in the pharmaceutical market.

What should investors watch during the earnings call?

Monitor operating margins, free cash flow trends, and management guidance on biosimilar competition. Pay attention to pipeline updates and any commentary on pricing power. The company’s ability to maintain margins while growing revenue will be critical for stock performance.

What does Meyka AI’s B+ grade mean for AMGN?

The B+ grade reflects solid fundamentals compared to S&P 500 benchmarks and sector peers. This grade factors in financial growth, key metrics, analyst consensus, and forecasts. It suggests AMGN is a reasonable investment but faces competitive and valuation pressures.

Is Amgen likely to beat or miss earnings?

Revenue beat appears probable given three consecutive quarters of outperformance and conservative guidance. EPS is less certain due to lower estimates. Strong margins and cash flow could support an EPS beat if revenue comes in above expectations.

Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.